Cardiac Considerations in Antidepressant Therapy

Risk Factors for Cardiac Effects

• Concomitant use of other medications that affect heart rate, such as beta-blockers, calcium channel blockers, and other QT-prolonging medications, is a risk factor for cardiac effects, as noted by the European Heart Journal and American Heart Association 1, 2, 3, 4
• Female gender, hypokalemia, bradycardia, congestive heart failure, baseline QT prolongation, and concomitant use of other QT-prolonging medications are risk factors for QT prolongation, according to the American College of Cardiology and European Society of Cardiology 3, 4, 5
• The American Heart Association and European Society of Cardiology recognize that citalopram's cardiac effects are dose-dependent and include risk of torsade de pointes, particularly at doses exceeding FDA recommendations or in overdose situations, with a clear dose-effect relationship existing between dose and QT prolongation in overdose 3, 4

Medication-Specific Cardiac Risks

• Citalopram has a higher risk of QT prolongation compared to paroxetine and sertraline, while escitalopram carries a possibly lower risk, and tricyclic antidepressants have different cardiac effects, including sodium channel blockade that can cause wide QRS and sinusoidal ventricular tachycardia, as reported by the European Heart Journal and American Heart Association 3, 2, 6, 5, 7
• Sertraline is well-studied in people with coronary heart disease and heart failure, appearing to be safe for these populations, and has demonstrated improvement in hemodynamic parameters in patients with cardiovascular conditions, as recognized by the American Heart Association 8, 9, 10
• Mirtazapine has been shown to be safe in cardiac patients, though efficacy data is limited, according to the American Heart Association 8, 11

Dosing and Monitoring Recommendations

• The FDA recommends a maximum dose of 40 mg/day (20 mg/day in patients >60 years) due to dose-dependent QT prolongation, and considers baseline and follow-up ECG monitoring in high-risk patients to be essential, with a QTc threshold for concern of >500 ms or an increase of >60 ms from baseline, as supported by the European Heart Rhythm Association 3, 5, 7
• The maximum recommended doses for citalopram and escitalopram are as follows:

• Monitoring plasma potassium levels to avoid hypokalemia and avoiding concurrent use of multiple QT-prolonging medications are recommended, according to the American College of Cardiology and European Society of Cardiology 5, 7

Pharmacokinetics and Discontinuation

• Escitalopram demonstrates rapid absorption with maximum plasma concentrations in 3-4 hours, an elimination half-life of 27-33 hours, supporting once-daily dosing, steady-state concentrations achieved within 7-10 days, and linear and dose-proportional pharmacokinetics in the 10-30 mg/day range, as reported by the manufacturer 12
• Gradual dose reduction rather than abrupt cessation is recommended when discontinuing treatment, and monitoring for signs of serotonin syndrome, clinical worsening, suicidality, and unusual behavior changes, especially during the first few months of therapy or at times of dose changes, as advised by the American Heart Association and FDA 13, 14, 15